Pollock N, Langton E E, Stowell K M, Bulger T F
Department of Anaesthesia, Palmerston North Hospital, Palmerston North, New Zealand.
Anaesth Intensive Care. 2011 Sep;39(5):887-94. doi: 10.1177/0310057X1103900514.
As the reliability of malignant hyperthermia normal in vitro contracture test results has been questioned, this study set out to determine the reliability of malignant hyperthermia normal results in New Zealand. Three hundred and twenty-nine anaesthetics were administered to malignant hyperthermia normal patients, identified through the Palmerston North Hospital malignant hyperthermia database. Anaesthetic records were retrieved and scrutinised for a malignant hyperthermia reaction using the Malignant Hyperthermia Clinical Grading Scale. Patients were exposed to one or more of eight triggering agents and multiple anaesthetic agents were administered in 41% of cases. Six variables were analysed, and although a minority of variables were abnormal in a small number of patients, none of the findings supported a malignant hyperthermia reaction. While the analysis was limited by the adequacy of the anaesthesia records, it was supported by negative DNA analysis in 55% of patients. This study supports several previous studies in demonstrating that patients in New Zealand tested non-susceptible to malignant hyperthermia can safely be given triggering agents.
由于恶性高热体外正常挛缩试验结果的可靠性受到质疑，本研究旨在确定新西兰恶性高热正常结果的可靠性。通过北帕默斯顿医院恶性高热数据库识别出的恶性高热正常患者接受了329次麻醉。检索麻醉记录，并使用恶性高热临床分级量表仔细检查是否有恶性高热反应。患者接触了八种触发剂中的一种或多种，41%的病例使用了多种麻醉剂。分析了六个变量，虽然少数患者的少数变量异常，但没有任何发现支持恶性高热反应。虽然分析受到麻醉记录充分性的限制，但55%的患者DNA分析结果为阴性，为该分析提供了支持。本研究支持了之前的几项研究，表明在新西兰经测试对恶性高热不敏感的患者可以安全地使用触发剂。
